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Renal bradykinin and vasopressin receptors: Ligand selectivity and
classification. We studied the specific binding of radiolabeled bradykinin
([3H]BK) and vasopressin ([3H]AVP) to membrane preparations of
bovine and porcine kidney medulla. [3HIBK reversibly labeled a single site
(Kd = 1.06 nM) in bovine kidney medulla independently of [Mg2]. The
number of BK receptors in bovine kidney medulla, Bmx = 122 fmol/mg
protein, is markedly (2- to 3-fold) higher than that reported in other
tissues. Further characterization by ligand binding indicated that the
bovine bradykinin receptor was the B2a subtype, pharmacologically related
to B2a receptors expressed by human and rabbit tissues. In contrast, the
specific binding of [3H]BK, but not [3H]AVP, to porcine kidney medulla(Kd = 0.32 flM, Bmax = 45 fmol/mg) was dependent upon the presence of
enzyme inhibitors to prevent the rapid and selective degradation of
bradykinin. Interspecies differences were revealed for renal medulla V2
vasopressin receptors with respect to their abundance and their affinity for
several V2-selective ligands. In summary, (I) bovine kidney medulla is a
convenient source of tissue for studying the B2 bradykinin receptor
subtype; (ii) there are significant species-dependent differences in both the
abundance of renal medulla B2a and V2 receptors and the ligand selectivity
of V2 receptors; and (iii) these findings are significant in relation to the
physiological and pathological roles of renal kinins and their interaction
with the neurohypophysial peptide hormone system.
Bradykinin (BK), kallidin (Lys-BK) and Met-Lys-BK are bio-
logically active kinins formed in tissues by the localized proteolytic
action of kallikriens on kininogen precursors [1—31. Kidney corti-
cal tissues actively synthesize kallikrein [4], and cytochemical and
immunohistological techniques have confirmed that kallikrein is
present on luminal and basolateral membranes of the distal
nephron [5—7]. Distal tubules and collecting ducts contain kinino-
gens [8], and it is known that the renal kallikrein-kinin system can
produce local concentrations of BK much higher than that of
blood [3, 9]. Indeed, this system is believed to play a major role in
the regulation of fluid and electrolyte balance, the failure of which
has been implicated as a causative factor in the development of
hypertension [2, 10—12].
Early studies indicated that the infusion of BK into the renal
artery produces both natriuresis and diuresis [13, 141. Further
evidence for a direct action of BK on tubular transport mecha-
nisms was provided by the observation [15] that kinins can
increase renal sodium excretion via a mechanism independent of
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BK-induced renal vasodilation. Additional studies have sought to
further define the renal actions of BK by the direct characteriza-
tion and localization of renal BK receptor subtypes [16—19].
However, in view of recent reports of BK receptor heterogeneity
[20—23], the ligand selectivity of renal BK receptors has remained
ill-defined. Moreover, there is evidence from studies in vitro
[24—26] that kinins can inhibit the action of vasopressin, while in
vivo the neurohypophysial peptide hormones may stimulate the
intrarenal formation of kinins [27, 28]. Thus, this study was
designed to address three fundamental questions relating to the
nature of renal bradykinin receptors and the potential interactive
roles of renal kinins and neurohypophysial peptide hormones.
Firstly, using binding assays and comparing ligand stability, we
assessed the utility of bovine and porcine kidney medulla as a
tissue source for direct studies of bradykinin and vasopressin
receptors by ligand binding. Secondly, and with reference to the
classification of other B2 receptors [23], we determined the
pharmacological characteristics of a bovine medulla B2 receptor
which we classified as the B2a subtype. Thirdly, due to the
physiologically relevant intrarenal interaction between bradykinin
and vasopressin receptors [24—28], we compared the ligand binding
parameters of bovine and porcine renal medulla V2 vasopressin
receptors and the ratio of B2a/V2 receptors in these tissues.
Methods
Materials
BK, kallidin, des-Arg9-BK, [7-D-phenylalanine]BK ([D-
Phe7]BK), [5-thienylalanine, 7-D-phenylalanine, 8-thienylala-
nine]BK ([Thi5'8,D-Phe7]BK), 0-D-arginine [3-hydroxyproline,
5-thenylalanine, 7-D-phenylalanine, 8-thienylalanine]BK (D-
Arg°[Hyp3,Thi5'8,D-Phe7]BK), bacitracin, bestatin, captopril, leu-
peptin, phenylmethylsulfonyl fluoride and 1,10-phenanthroline
were from Sigma (Poole, Dorset, UK). [3-hydroxyproline]BK
([Hyp3]BK), 0-D-arginine [3-hydroxyproline, 5-thienylalanine,
7-D-(1,2,3,4-tetrahydroisoquinoline-3-yl-carbonyl],8-[(3a5,7a5)-octa-
hydroindol-2-yl-carbonyl]]BK (D-Arg°[Hyp3,Thi5,D-Tic7,Oic8jBK,
Hoe 140), [8-arginine]vasopressin (AVP), 0-(valine-aspartic acid)-
AVP (Val-Asp-AVP) and [1-f3-mercapto-j3-cyclopentamethyl-
enepropionic acid, 2-D-isoleucine, 4-isoleucine]AVP ([d(CH2)5D-
11e2,11e4]AVP) were from Bachem (Torrance, cA, USA).
[7-aminoisobutyric acid]BK ([Aib7]BK) was a kind gift from
Professor D. Regoli. 0-D-arginine-[3-hydroxyproline, 7-D-phenyl-
alanine, 8-leucine]BK (D-Arg°[Hyp3,D-Phe7,Leu8}BK) was from
Neosystem Laboratoire (Strasbourg, France). 1 -deamino-AVP
(dAVP) was from Ferring Pharmaceuticals (Malmo, Sweden) and
586
Howl et al: Renal bradykinin and vasopressin receptors 587
1-deamino- [4-valine, 8-D-arginine]AVP (dVDAVP) was from
Penninsula Laboratories (Belmont, CA, USA). The non-peptide
bradykinin antagonist, phosphonium, [ [4-[ [2-(S]-amino]-3-(2-
naphthylenyl)-1-oxopropyl]methylltributyl-, chloride, monohydro-
chloride (WIN 64338) was a kind gift from Sanofi Winthrop
(Guildford, Surrey, UK). All peptide ligands were dissolved in
0.05% (vol/vol) acetic acid as 1 m stock solutions. WIN 64338
was prepared as a 10 m stock in dimethylsulfoxide. All receptor
ligands were stored at —20°C.
Preparation of kidney medulla membranes
Bovine and porcine kidneys were obtained from a local abat-
toir, transported on ice, and further processed within one hour.
Kidney medulla was carefully dissected to ensure the complete
absence of cortical contamination. Membranes were prepared as
previously described [291 using a protocol based upon that first
described by Bockaert et al [30] and employing bacitracin (1
mg!ml) as a broad spectrum protease inhibitor during the initial
homogenization of tissue. The protein content of membrane
preparations was determined using the Pierce BCA assay (Pierce,
Rockford, IL, USA) with a bovine serum albumin (BSA) stan-
dard. Membrane aliquots were stored at —20°C.
Ligand binding to bradykinin and vasopressin receptors
Binding assays were performed as previously described [29, 311,
using [Pro2'3-3,4(n)-3H]BK 76.0 Ci!mmol, Amersham, Little Chal-
font (Bucks, UK) and [Phe3-3,4,5-3H]AVP ([3H]AVP) 64.8 Ci!
mmol (DuPont NEN, Stevenage, Herts, UK) as tracer ligands.
Kidney medulla membranes were diluted to give a final concen-
tration of either 230 j.tg total protein (bovine) or 100 ig total
protein (porcine) in a final volume of 500 j.tl buffer A [20 mM
Hepes, 10 mrvi Mg(CH3COO)2 1 mtvt EGTA, 0.1% (wt/vol) BSA,
pH 7.4] [31]. Unless otherwise indicated, binding assays were for
90 minutes at 30°C, which allowed equilibrium binding to be
established. The dissociation binding constants (Kd) of unlabeled
peptides were calculated from IC50 values determined by compe-
tition binding according to the method of Cheng and Prusoff [321.
To determine the influence of [Mg2] on the binding of [3H]BK
to bovine kidney medulla (BKM), membranes were thawed on ice
and sedimented by centrifugation (13,000 X g, 5 mm) at 4°C.
Membranes were suspended by homogenization in 100 volumes of
cold buffer B (20 mt Hepes, 1 mM EGTA, 10 mrvi EDTA, pH 7.4)
and stored on ice for 10 minutes to allow efficient chelation of
Mg2. This process was repeated before a final suspension in
buffer A without EDTA. For binding assays, membranes were
suspended in buffer A containing 0 to 20 mrvt Mg(CH3COO)2.
Buffer containing no Mg2 was supplemented with 5 mM EDTA.
Assessment of ligand stability
Analytical HPLC of the peptides BK and AVP utilized an
analytical C18 Spherisorb ODS reverse-phase column (4.6 X 250
mm; Phase Separations, Deeside, UK). Peptides (20 nmoles) were
eluted using a linear 30 minutes gradient of 5 to 65% acetonitrile!
0.1% (vol/vol) trifluoroacetic acid at a flow rate of 1.5 ml/min [29].
Peptides were detected by monitoring the eluate at 220 nm.
Peptide stability in the presence of BKM and porcine kidney
medulla (PKM) membranes was determined by comparing the
elution profiles of both BK and AVP before and after incubation
with membranes under identical conditions to those used for
binding assays. Membranes were sedimented (13,000 X g, 5 mm)
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Fig. 1. Saturable binding of [3HJBK to a membrane preparation of BKM.
Each point is the mean of triplicate determinations. Error bars indicate
SEM. Specific binding (LI) was calculated as the difference between total
binding () and non-specific binding (0) defined by 4 !LM unlabeled BK.
Binding parameters were measured at a total of 12 concentrations of
[3H]BK. A one-site binding isotherm was fitted to experimental data using
least-squares non-linear regression (Fig. P. program, Biosoft) to define the
parameters of specific binding (parameter 95% confidence limit): Kd
1.47 0.37 flM, Bmax = 122 11 fmol!mg protein.
and the supernatant filtered through a 0.2 j.rm filter before
injection onto the HPLC column.
Results
Characterization and classification of a bovine kidney medulla
bradykinin receptor
Investigations revealed that a large fraction (> 70%) of the
binding of 0.45 to 0.55 nM [3H]BK to BKM membranes was
displaced by excess (4 1LM) unlabeled BK. Saturation binding
analysis (Fig. 1) demonstrated that the specific binding of [3H]BK
to BKM membranes was saturable, of high affinity and to a single
class of receptor with a capacity of 122 11 fmol!mg protein (Fig.
1). The K. of [3HIBK binding determined by saturation analysis
was 1.47 0.37 nM, a value which compared favorably with a
mean of 1.06 0.12 flM derived by homologous displacement
(Fig. 4). The binding of [3HIBK to this receptor was further
characterized by kinetic analysis (Fig. 2). These data revealed that
the equilibrium binding of [3HIBK was consistent with the forma-
tion of a fully dissociating ligand:receptor complex. This investi-
gation also confirmed that [3H]BK was stable under the condi-
tions used. As indicated in Figure 3, the effect of [Mg2] on the
binding parameters of [3H]BK to BKM membranes was restricted
to a concentration-dependent reduction in non-specific binding.
The specific binding of [3H]BK to the BKM bradykinin receptor
(BKR) was independent of [Mg2] over the range of 0 to 20 mtvi
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Fig. 2. Association (1) and dissociation (A) kinetics of specific / 3HJBK
(0.54 nM) binding to BKZvI membranes. Each point is the mean of triplicate
determinations SEM. Non-specific binding was determined by 4 sM
unlabeled BK. Dissociation of [3H]BK was measured following the
addition of Hyp3]BK (3 jsM final concentration) to some tubes at the time
indicated by the arrow.
(Fig. 3). The bovine receptor was further characterized by homol-
ogous and heterologous ligand displacement analysis using a
range of selective and non-selective BK analogues (Fig. 4). The
lack of displacement of [3H]BK by the B1-selective agonist
Des-Arg9-BK (10 /kM) revealed the complete absence of B1
receptors in the BKM preparation. The binding affinities of
bradykinin agonists for this bovine receptor exhibited the follow-
ing rank order: [Hyp3]BK  BK  kallidin >> [Aib7JBK >>
Des-Arg9-BK. Of the antagonists used in this study, Hoe 140
displayed an extremely high affinity Kd = 0.101 0.011 nM (N =
3). Comparison of the binding affinities of BK analogues for the
bovine BKR with data from a cloned human B2 BKR revealed a
close correlation (Fig. 5).
Peptide stability
Initially, we failed to observe any specific binding when [3H]BK
(0.45 to 0.55 nM) was incubated with PKM membranes using
optimum conditions determined for the BKM preparation. To
assess if this was due to proteolytic breakdown of BK, we used
HPLC to quantitatively analyze the degradation of BK and AVP
during incubation with both BKM and PKM membranes (Fig. 6).
As indicated by the results obtained from binding assays, we
confirmed that both BK and AVP were completely stable during
incubation with BKM membranes. In contrast, HPLC analysis
revealed that BK, but not AVP, was degraded by PKM mem-
branes (Fig. 6). A cocktail of protease inhibitors consisting of
bacitracin 0.1 mg/mI, bestatin 3 g/ml, captopril 10 j.LM, leupeptin
5 g/ml, 1,10-phenanthroline 1 mivi, phenylmethysulfonyl fluoride
1 mM (final concentrations) was added to the incubations. This
completely inhibited BK degradation in the PKM preparation
(Fig. 6). Use of this enzyme inhibitor cocktail allowed the binding
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Fig. 3. Effect of [Mg2] on the binding parameters of [3HJBK (0.63 nM) in
BKM membranes. Non-specific binding was defined by 4 /LM unlabeled BK.
Symbols are: () total binding; () non-specific binding. Values are
means SEM (N = 3).
parameters of [3H]BK to the PKM bradykinin receptor to be
established. Homologous displacement experiments revealed that
the porcine receptor bound BK with high affinity (Kd = 0.32
0.18 nM, N = 3). The capacity (Bmax) of BKRs in the PKM
preparation was 45 fmol/mg protein, approximately one third that
of the bovine preparation.
Comparative pharmacology of bovine and porcine V2 vasopressin
receptors (VPRs)
To further characterize the kidney medulla preparations used
in this study, we compared the binding of vasopressin receptor
ligands in both species. We confirmed, as previously reported for
the BKPvI preparation [31], that the Via-selective radioligand [3H]
[1--mercapto-/3,/3-cyclopentamethylenepropionic acid, 2-0-
methyltyrosine]AVP [33] (0.1 to 0.13 nM) did not specifically label
a VPR in either preparation. Since Via VPRs are expressed in
kidney cortex, these data indicated the absence of cortical con-
tamination in either membrane preparation. Both kidney medulla
preparations were found to be suitable for the direct study of V2
VPRs using [3H]AVP (0.4 to 0.8 nM) as a radioligand. The
comparative ligand binding selectivity of bovine and porcine V2
VPRs is summarised in Table 1. Significantly, the agonists AVP
and dAVP bound with similar affinity to both V2 receptors while
the affinity of the V2-selective agonist dVDAVP was found to be
some 220-fold lower at the porcine V2 VPR compared with the
bovine V2 VPR. Both receptors displayed similar and relatively
low affinity for the V2-selective antagonist [d(CH2)5D-
11e2,11e4]AVP and for Val-Asp-AVP (Table 1).
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Fig. 4. Displacement of specific [3H]BK binding to the bovine B2a BKR by
BK analogues. Points are means SEM of triplicate determinations. The
dissociation binding constants (K.) of unlabeled ligands were calculated
from experimentally determined IC50 values using a value for the K of
bradykiniN 1.06 nM. K.d values are means SEM from 3 to 5
independent determinations. Free [3HBK ranged from 0.45 n to 0.60
nM. Symbols are: (S) D-Arg°[Hyp3,Thi ,D-Tic7,Oic8]BK (Hoe 140), Kd
0.101 0.011 nM; (•) [Hyp3IBK, Kd = 0.86 0.20 nM; (A) BK, K.2 = 1.06
0.12 nM; (V) kallidin, Kd = 1.50 0.18 nas; (•) D-Arg°[Hyp3,D-
Phe7,Leu8]BK, Kd =2.84 0.17 nat; (•) D-Arg°[Hyp3,Thi58,D-Phe7]BK,
Kd = 9.40 0.85 nM; (0) [D-Phe7]BK, K..2 = 124 11 nM; (Eli) [Aib7]BK,
= 184 32 nM; () [Thi5'8,D-Phe7]BK, Kd = 491 82 nM; (V) WIN
64338, Kd = 5,830 430 nM; (<I>) Des-Arg9-BK, Kd> 10,000 nM.
Discussion
In many tissue and cell preparations the characterization of
kinin receptors using the direct approach of ligand binding is
hampered by the lability of BK analogues [3, 17, 19, 34, 35] and by
the low abundance of binding sites [36-38]. The stability of BK in
the presence of BKM membranes in this study may be due in part
to the method we used for tissue preparation. Precautions to
prevent proteolytic activity were taken and included the addition
of bacitracin as a general protease inhibitor and multiple tissue
washes to remove soluble proteins. Although porcine medulla was
processed using exactly the same protocol employed for preparing
PKM membranes, BK was unstable when exposed to this tissue.
This proteolytic cleavage was specific to BK as AVP was not a
substrate for proteolysis. Consequently, the specific binding of
[3H]BK to renal membranes from many species including pig (this
study), rat [19] and guinea pig [17] is dependent upon the addition
of protease inhibitors. An additional advantage afforded by the
BKM preparation is the level of receptor expression (122 fmol/mg
protein), which is higher than that reported in any other tissue
including rat glomerulus (31 fmol/mg protein) [19], guinea pig
medulla (14 pmol/g wet wt) [17], rabbit collecting tubule (73
fmol/mg protein) [161 and PKM (45 fmol/mg protein, this study).
Despite reports of multiple receptor sites in guinea pig kidney
medulla [17] and other tissues [38—40], we found no evidence for
multiple B2 receptors in BKM or PKM. However, our finding
concurs with other studies which have indicated the expression of
a single subtype of B2 BKR in rat glomerulus [19], rabbit
collecting tubule [161 and cultured renomedullary interstitial cells
[35]. The measured high concentration of BKRs in BKM is
consistent with the selective localization of B2 BKRs to medullary
collecting tubules [2, 7, 18]. Optimal binding of [3H]AVP to VPRs
requires Mg2 in millimolar concentrations [41, 42]. However, the
specific binding of [3H]BK to the BKR in BKM was independent
of [Mg2]. The only observed effect of increasing [Mg2] was a
decrease in the level of non-specific binding, an effect presumably
due to the reduced non-specific interaction of BK (a basic
peptide) with negatively charged sites.
Heterogeneity of BKRs is a widely reported phenomenon
[20—23, 39, 43]. B1 BKRs are relatively poorly understood but can
be distinguished from B2 receptors by their sensitivity to des-Arg9-
metabolites of BK or kallidin. Thus, the observation that des-
Arg9-BK displays extremely low affinity for the BKR in BKM
indicates the absence of B1 BKRs in the bovine preparation.
Regoli and coworkers [22, 23] have further classified two well
characterized BKR systems as B2a (rabbit jugular vein, RJV) and
B2b (guinea pig ileum, GPI) using data derived from bioassays
with both agonists and antagonists. Our findings endorse this
classification scheme and indicate that the B2 BKR in BKM
should be classified as the B2a subtype. The reasons for this are
threefold. Firstly, the rank order of agonist binding affinities to the
B2 BKR in BKM is [Hyp3]BK  BK  kallidin >> [Aib7]BK>>
des-Arg9-BK. These data correlate well with the observed order of
potency of the same agonists in RJV but differ markedly from that
in GPI [22, 23]. The relatively low affinity (Kd = 184 nat) of the
B2h-selective agonist [Aib7]BK in BKM is particularly diagnostic
in this regard and correlates with a measured potency (pD2 =
6.28) in the RJV, which is almost two orders of magnitude lower
than that in GPI [23]. In fact, [Aib7}BK is almost equipotent to BK
and more potent than [Hyp3]BK in the B2b BKR system of the
GPI [23]. Secondly, the measured binding affinities of selective
antagonists also support the classification of the BKR in BKM as
the B2a subtype. D-Arg°[Hyp3,D-Phe7,Leu8]BK, which binds with
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Fig. 5. Correlation of binding data of bovine and human BKRs. Data for
the cloned human B2 BKR are taken from Eggerickx et al [44]. r = 0.92.
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high affinity to the BKR in BKM (Kd = 2.84 nM), is a potent
antagonist at the B2 receptor in RJV (pA2 = 8.86) but much
weaker at the B2h receptor in GPI (pA2 = 6.77) [23]. Conversely,
WIN 64338, a potent B2h-selective antagonist which only weakly
antagonizes BK in RJV [23] exhibited very low affinity (Kd = 5.83
/LM) for the BKR in BKM. Thirdly, the measured binding affinities
of selective and non-selective ligands for the BKR in BKIvI
correlate with data obtained with a cloned human B2 receptor of
unknown tissue origin [44]. A positive correlation between data of
the same cloned human B2 BKR and the RJV B2a BKR has been
previously reported [23]. We conclude that B2 BKRs expressed in
these various bovine, human and rabbit tissues are the same B2
subtype.
Previous reports have provided evidence that both B1 and B2
BKRs have a role in kinin-dependent modulation of renal func-
tion [36, 45, 46]. Significantly, the density of B2 BKRs in rat
glomerular membranes is reduced following a low sodium diet
[36] and increased in two-kidney, one-clip Goldblatt hypertensive
rats [47]. These data indicate that the density of renal BKRs is
critically regulated and provide clues to the involvement of the
kallikrein-kinin system in the regulation of Na excretion and
development of hypertension. As reviewed by Majima and Katori
Dissociation binding constant
(Kd nM)
Bovine Porcine
Bmax = 59 B,,,ax = 298
Peptide fmol/mg fmol/mg
AVP 0.68 0.09° 1.32 0.10
dAVP 5.43 3.91 0.94 0.22
[d(CH2)5D-Ile2,IIe4IAVP 478 20l 924 9
dVDAVP 0.56 0.10 124 7
Val-Asp-AVP 562 80 871 99
[2], the kallikrein-kinin system regulates both glomerular filtration
rate and Na-reabsorbtion in the kidney collecting tubule. Thus,
reduced activity of the kallikrein-kinin system may lead to the
BK
B
I I I
D
15
Fig. 6. HPLC elution profiles of bradykinin (BK)
and [Arg8Jvasopressin (A VP). A. Elution of
peptides (20 nmoles each) after 90 minutes
incubation with BKM membranes at 30°C. B.
Elution at time 0 immediately after mixing
peptides with PKM membranes. C. Elution
after 90 minutes incubation with PKM
membranes in the absence of protease
inhibitors. BK is selectively degraded under
these conditions. D. Elution after 90 minutes
incubation with PKM membranes with protease
inhibitors. The selective proteolytic degradation
of BK observed in C is inhibited. Ordinate,
20 25 15 20 25 Abs22() (arbitrary units), abscissa, time (mm).
Table 1. Comparative pharmacology of bovine and porcine kidney
medulla V2 vasopressin receptors
AVP, [p8-arginine]vasopressin; dAVP, 1-deamino-AVP; [d(CH2)5,D-
Ile2,11e4]AVP, [1-!3-mercapto-/3,f3-cyclopentamethylenepropionic acid,2-
D-isoleucine,4-isoleucine]AVP; dVDAVP 1-deamino-[4-valine,8-D-argi-
ninelvasopressin;Val-Asp-AVP, 0-(valine-aspartic acid)-AVP. Values are
means SEM (N = 3 to 5).
° Previously reported in [311b Previously reported in [561
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development of hypertension through Na accumulation [2, 10,
11]. There is additional evidence that increased renal concentra-
tions of kinins in young spontaneously hypertensive rats have a
causative role in the pathogenesis of hypertension [34, 48]. Our
findings indicate that the application of B2a-selective BK ana-
logues such as D-Arg°[Hyp3,D-Phe7,Leu8]BK may offer advan-
tages over the use of non-selective ligands such as Hoe 140
[49—51] in future studies to unravel the complex role of kinins in
renal function and for the development of therapeutic agents [52].
Bradykinin acts on receptors expressed by renal medulla inter-
stitial cells [181 to generate prostaglandins [53]. Prostaglandins,
including PGE2, antagonize the effects of vasopressin on collect-
ing ducts [54] and inhibit sodium reabsorption by collecting
tubules [55], provoking diuresis and natriuresis. Moreover, the
expression of V2 vasopressin receptors is localized to principal
cells of the collecting duct [56, 571. Thus, it is likely that the kidney
medulla preparations used in this study contain membranes
derived from a variety of cell types including both interstitial cells
and collecting ducts. Species-dependent differences in the affinity
of some neurohypophysial peptide hormone analogues for kidney
medulla V2 VPRs have been reported elsewhere [58, 59]. Our
data indicate for the first time that the V2-selective antagonist
[d(CH7)5D-Ile2Ile4]AVP binds with relatively low affinity to both
bovine and porcine V2 VPRs when compared with data from rat
[59]. Val-Asp-AVP, an N-terminal extended analogue of AVP
isolated from bovine neurohypophysis [60], also displays very low
affinity for bovine and porcine V2 VPRs. These data are consistent
with the hypothesis [60] that Val-Asp-AVP may be a storage form
intermediate in the synthesis of AVP rather than the active agent.
Despite pharmacological differences in the binding affinities of
vasopressin analogues, in all species studied to date agonist
occupancy of kidney medulla V2 VPRs stimulates adenylate
cyclase [30, 61, 621. Intriguingly, our data indicate a significant
species-dependent difference in the ratio of the levels of expres-
sion of B2a BKRs and V2 VPRs in normal bovine (2:1) and
porcine (0.2:1) kidney medulla. In view of the likely intrarenal
interaction of kinins and neurohypophysial hormones (see above),
we suggest that the combined application of B2a-selective BK
analogues and V2-selective AVP analogues could be a powerful
approach to unveiling the physiological and pathophysiological
role(s) of renal kinins.
In conclusion, we have identified a BKR which is expressed by
BKM at relatively high abundance. This receptor was pharmaco-
logically characterized as the B2a subtype. In addition, we have
shown that the ratio of B2a BKR:V2 VPR is species dependent
and that this may have physiological ramifications.
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